朝聚眼科(02219.HK)香港公開發售獲113.97倍認購 上限定價每股10.6港元
格隆匯7月6日丨朝聚眼科(02219.HK)發佈公吿,公司全球發售1.7093億股股份,其中香港發售股份8546.5萬股,國際發售股份8546.5萬股,另有15%超額配股權;發售價已釐定為每股發售股份10.60港元,每手買賣單位500股;海通國際及華泰國際為聯席保薦人,預期股份將於2021年7月7日於聯交所主板掛牌上市。
根據國際發售初步提呈發售的發售股份已獲大幅超額認購約17.83倍。根據香港公開發售初步提呈發售的發售股份已獲非常大幅超額認購。合共接獲153,275份有效申請,認購合共19.48億股,相當於根據香港公開發售初步可供認購的香港發售股份總數約113.97倍。
基於發售價每股發售股份10.60港元計算,根據基石投資協議,基石投資者已認購合共7467.45萬股發售股份,合共佔緊隨全球發售完成後公司已發行股本約10.86%;及全球發售項下發售股份數目約43.69%(假設超額配股權未獲行使)。
基於發售價每股發售股份10.60港元計算,根據最新估計,公司自全球發售收取的所得款項淨額估計約為13.571億港元(假設超額配股權未獲行使)。其中,公司擬將所得款項淨額約35.8%將用於建立新醫院以及搬遷、升級及裝修現有醫院;約44.8%將在出現合適機遇時,用於在人口龐大且對眼科醫療服務需求相對較高的新市場中收購醫院;約9.4%將用於升級公司的信息技術系統;及約10.0%將用於營運資金及其他一般企業用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.